pleasehaa.blogg.se

Programmed cell death ligand 1 (PD-L1) inhibitor (durvalumab and atezolizumab) plus etoposide-based chemotherapy, compared with etoposide-based chemotherapy alone, showed the most favorable OS (hazard ratio, 1.40 95% CI, 1.09-1.80) and the best DCR (odds ratio, 0.42 95% CI, 0.21-0.81). Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study collection, management, analysis, and interpretation of the data preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.Īdditional Information: The data sets used and analyzed during the current study are available from the corresponding authors on reasonable request.Ī total of 3 phase 2 and 11 phase 3 randomized clinical trials involving 4838 patients were included. Zhang.Ĭonflict of Interest Disclosures: None reported.įunding/Support: This work was supported by grants 2016YFC09055YFC0905503 from the National Key Research and Development Program of China, grant 2017B020227001 from the Science and Technology Program of Guangdong, grant 201607020031 from the Science and Technology Program of Guangzhou, grant 81772476 from the Chinese National Natural Science Foundation Project, grant 2018A030313838 from the Natural Science Foundation of Guangdong Province of China, and grant 2016001 from the 5010 Clinical Research Foundation of Sun Yat-sen University. Zhang, Luo, Wang.Īdministrative, technical, or material support: Zhou, Z. Zhang, Luo, Wang.Ĭritical revision of the manuscript for important intellectual content: Z. Zhao.ĭrafting of the manuscript: Zhou, Z.

Zhang.Īcquisition, analysis, or interpretation of data: Z.

Zhang, and Luo contributed equally to this work.Ĭoncept and design: Zhou, Z.

Zhang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Corresponding Authors: Yan Huang, PhD ( and Li Zhang, PhD ( Department of Medical Oncology, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China, 651 Dongfeng Rd E, Guangzhou, Guangdong 510060, PR China.Īuthor Contributions: Drs Zhou and Z.